We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Bilanz Novartis 2023: Fürs Herz und gegen Krebs.
- Authors
Bulmahn, Maren
- Abstract
The pharmaceutical company Novartis achieved a revenue of 45.4 billion US dollars in 2023, which corresponds to a growth of 10 percent. The increase in revenue was mainly achieved through the heart medication Entresto, the medication Kesimpta for the treatment of multiple sclerosis, as well as the anticancer drugs Kisqali and Pluvicto. Novartis has separated from its generic activities and is now focusing on the areas of immunology, neurology, oncology, as well as cardiovascular, renal, and metabolic diseases. In Germany, the company has approximately 2600 employees at various locations. Earnings per share increased by 70 percent and the dividend is expected to be increased by 3.1 percent.
- Subjects
GERMANY; EARNINGS per share; NOVARTIS AG; ANTINEOPLASTIC agents; U.S. dollar; BUSINESS revenue; ENTRESTO
- Publication
Nachrichten aus der Chemie, 2024, Vol 72, Issue 4, p41
- ISSN
1439-9598
- Publication type
Article
- DOI
10.1002/nadc.20244140771